Skip to search formSkip to main contentSkip to account menu

AZD2014

Known as: AZD 2014, AZD-2014 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

MorpholinesVistusertib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Allosteric and ATP-Competitive Inhibitors of mTOR Effectively Suppress Tumor Progression-Associated Epithelial-Mesenchymal Transition in the Kidneys of Tsc2+/− Mice
2018
2018
CC-223 inhibits human head and neck squamous cell carcinoma cell growth.
2018
2018
Selumetinib-based therapy in uveal melanoma patient-derived xenografts
The prognosis of metastatic uveal melanoma (UM) is among the worst of all human cancers. The identification of near-ubiquitous… 
2017
2017
MHY1485 ameliorates UV-induced skin cell damages via activating mTOR-Nrf2 signaling
Ultra Violet (UV)-caused skin cell damage is a main cause of skin cancer. Here, we studied the activity of MHY1485, a mTOR… 
2017
2017
Influence of the Novel ATP-Competitive Dual mTORC1/2 Inhibitor AZD2014 on Immune Cell Populations and Heart Allograft Rejection
Background Little is known about how new-generation adenosine triphosphate–competitive mechanistic target of rapamycin (mTOR… 
2017
2017
OCTOPUS: A randomised, multi-centre phase II umbrella trial of weekly paclitaxel+/- novel agents in platinum-resistant ovarian cancer—Vistusertib (AZD2014).
TPS5609Background: There is an urgent need to improve outcomes for patients with platinum-resistant and refractory ovarian cancer… 
2016
2016
mTOR inhibition sensitizes human hepatocellular carcinoma cells to resminostat.
2016
2016
Abstract OT1-03-12: MANTA: A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or…
Background: Resistance to endocrine therapy remains a major clinical challenge with aberrant PI3K/ mTOR pathway activation being… 
2016
2016
Insights into significance of combined inhibition of MEK and m-TOR signalling output in KRAS mutant non-small-cell lung cancer
Background:We aimed to understand the dependence of MEK and m-TOR inhibition in EGFRWT/ALKnon-rearranged NSCLC cell lines.Methods… 
2015
2015
Abstract CT138: Translating preclinical observations to the clinic: Combination of the dual m-TORC1/2 inhibitor AZD2014 and paclitaxel in ovarian and lung cancer
Background: We have previously immunomagnetically separated cancer cells from ascites samples of patients with ovarian cancer who… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)